ALK

Notes

original target text: ALK inhibitor

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase, a type of cell-surface protein that normally transmits growth signals into cells after being activated by specific binding partners. In certain cancers, chromosomal rearrangements fuse the ALK gene to another gene, producing an abnormal, permanently active version of the protein that continues to signal for cell growth and survival even without the usual activating signal. This constitutive activity drives proliferation of tumor cells and helps them resist normal controls on cell division and programmed cell death. Small-molecule ALK inhibitors are designed to occupy the kinase's active site, blocking its enzymatic activity and interrupting the downstream signaling cascades that promote tumor growth. This mechanism is most relevant in cancers where an ALK gene fusion is the primary driver of malignancy, most notably a subset of non-small cell lung cancer and a form of lymphoma called anaplastic large cell lymphoma. Because these fusions are typically absent from healthy tissue, ALK inhibition is considered a targeted approach, aiming to act selectively on tumor cells that depend on this aberrant signaling while sparing normal cells that do not express the fusion protein. Multiple generations of ALK inhibitors have been developed, reflecting ongoing efforts to improve potency, tissue penetration, and activity against resistant mutant forms of the fusion protein.